Latest News

Analysis of 20 years of data highlights differences in reimbursement trends across ophthalmology subspecialties and practice settings, according to Dustin D. French, PhD.

Broadwood and Yunqi Capital will add 3 total members to the board, while the CEO and more step down.

A total of 38 patients were included in the study. All underwent implantation of the PRIMAretinal prosthetic chip with the goal of restoring vision.

The trial is evaluating OCU410 (AAV5-RORA) for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD).

Key clinical trial data and PDUFA dates in early 2026 focus on treatments for dry eye, AMD, and rare eye diseases.

The Swiss-designed phaco platform provides mobility, simplified workflows, and reduced surgical waste for cataract procedures, according to the company.

OCU410ST uses an adeno-associated virus delivery platform for the retinal delivery of the RORA gene.

Formerly, the EDOF technology was specifically limited to intraocular lenses.

Patients underwent a full ophthalmologic examination that included optical coherence tomography (OCT), OCT angiography, and biometry.

“Remarkable” results were reportedly obtained with hypotony with hydroxypropyl methylcellulose.

The Part B dose-expansion portion is evaluating SB-007 for the treatment of Stargardt disease.

As Glaucoma Awareness Month highlights evolving practice, specialists describe how artificial intelligence, sustained drug delivery, laser therapy, and workflow integration are reshaping earlier, more individualized glaucoma care.